Brainsway USA INC
$326.1K 242 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc. reported $326,053.24 across General Payments, Research, and Ownership to 188 physicians and teaching hospitals across 188 transactions.
- $326.1K Above-median payer
- All-tracks total
- 188 Above-median volume
- Transactions
- 188 Above-median reach
- Recipients
- +$31.9K
- General Payments vs PY2023
BioCryst Pharmaceuticals, Inc. reported $326,053.24 across all CMS Open Payments tracks (General + Research + Ownership) to 188 physicians and teaching hospitals in Program Year 2024 - ranking #875 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $326,053.24, averaging $1.7K per recipient.
BioCryst Pharmaceuticals, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
21/100
Total payments
F
13/100
Transaction volume
F
11/100
Physician reach
F
11/100
Payment type diversity
D
50/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer biocryst-pharmaceuticals-inc BioCryst Pharmaceuticals, Inc.
$326.1K · #875/1,925 · 0.0% industry · PY2024
- TOT $326.1K
- RANK #875
- SHARE 0.0%
- TXN 188
- RCP 188
- CAT 4
- GEN $326.1K
- ΔGEN +$31.9K
- TOP1 21.2%
- PY 2024
Volume peers
Nearest volume peer: Brainsway USA INC ($326.1K)
BioCryst Pharmaceuticals, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
BioCryst Pharmaceuticals, Inc.'s CMS-reported General Payments increased by $31.9K (+10.8%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: BIOCRYST PHARMACEUTICALS, INC.PY2023: BIOCRYST PHARMACEUTICALS, INC.PY2024: BioCryst Pharmaceuticals, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $294,187.70
- PY2024
- $326,053.24
What the Data Shows for BioCryst Pharmaceuticals, Inc.
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For BioCryst Pharmaceuticals, Inc. that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
The 4-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Consulting Fee" at $171.1K, accounting for 52.5% of this company's General Payments and 92 transactions.
General Payment Breakdown by Type
BioCryst Pharmaceuticals, Inc. made 4 types of general payments. "Consulting Fee" is the largest category at $171.1K, 52.5% of General Payments.
BioCryst Pharmaceuticals, Inc. reports 4 general-payment categories - the top three are Consulting Fee (52.5%), Compensation for Services Other Than Consulting (42.0%), and Travel and Lodging (5.0%). The remaining 1 category make up 0.5% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How BioCryst Pharmaceuticals, Inc. divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $171.1K | 92 | 52.5% |
| Compensation for Services Other Than Consulting | $136.9K | 37 | 42.0% |
| Travel and Lodging | $16.4K | 36 | 5.0% |
| Food and Beverage | $1.7K | 23 | 0.5% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $201,916.83 (61.9%) of $326,053.24 in this company's General Payments records across 67 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for BioCryst Pharmaceuticals, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Steven Galson
$69,146.39 across 17 reported transactions
- 2
Amy Mckee
$66,666.01 across 19 reported transactions
- 3
Wendy Yee
$32,834.85 across 5 reported transactions
- 4
Amer Zeidan
$21,000.00 across 1 reported transactions
- 5
Donald Fong
$12,269.58 across 3 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
BioCryst Pharmaceuticals, Inc.'s spend rank (#875 of 1,925, top 45% by spend) and concentration rank (#1,001 of 1,838, bottom 46% least concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- CurvaFix, Inc. : $140.6K total payments, HHI 1090
- SpringWorks Therapeutics, Inc. : $1.4M total payments, HHI 1087
- Ion Beam Applications S.A. : $32.3K total payments, HHI 1083
- Cumberland Pharmaceuticals, Inc. : $341.4K total payments, HHI 1083
- Cook Incorporated : $6.0M total payments, HHI 1081
- Grifols Shared Services North America, Inc. : $105.0K total payments, HHI 1080
- BioCryst Pharmaceuticals, Inc. (this company) : $326.1K total payments, HHI 1076
- Vektor Medical Inc. : $86.8K total payments, HHI 1068
- Magenta Medical Inc : $47.9K total payments, HHI 1068
- Galvanize Therapeutics, Inc : $228.2K total payments, HHI 1067
- Mesh Suture Inc : $11.2K total payments, HHI 1063
- Akebia Therapeutics Inc : $497.0K total payments, HHI 1056
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as BioCryst Pharmaceuticals, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about BioCryst Pharmaceuticals, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with BioCryst Pharmaceuticals, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Endogastric Solutions, Inc
$325.4K 933 recipients
Compare payment profiles
DeGen Medical, Inc.
$324.9K 204 recipients
Compare payment profiles
Life Spine, Inc.
$327.4K 429 recipients
Compare payment profiles
AMAG Pharmaceuticals, Inc.
$327.8K 8 recipients
Compare payment profiles
MedAlliance LLC
$323.3K 0 recipients
Compare payment profiles
Put this to use
BioCryst Pharmaceuticals, Inc. ranks #875 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just BioCryst Pharmaceuticals, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.